Zhaoke Ophthalmology's (HKG:6622) carbachol and brimonidine tartrate ophthalmic solution met its prespecified primary endpoint in a phase II trial in China.
The treatment was well tolerated with a favorable safety profile, according to a Friday Hong Kong bourse filing.
The drug is an eye drop formulation designed to restore near vision loss due to presbyopia.
The company intends to discuss advancing a phase III study with China's National Medical Products Administration.